For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
This study will be the initial exploration of APL-2 in patients with PNH. The assessments of the safety, tolerability, PK, and PD following administration of single and multiples doses of APL-2 will guide decisions to further develop the drug.
Wed, 10/01/2014 to Wed, 06/01/2016
Bone Marrow Disease(s):
paroxysmal nocturnal hemoglobinuria (PNH)